Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Short Interest Up 52.0% in March

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 17,040,000 shares, an increase of 52.0% from the March 15th total of 11,210,000 shares. Based on an average trading volume of 2,810,000 shares, the days-to-cover ratio is presently 6.1 days. Approximately 12.0% of the company's stock are sold short.

Insider Buying and Selling

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the company's stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares in the company, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.56% of the stock is owned by insiders.

Institutional Investors Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently made changes to their positions in XERS. NewEdge Advisors LLC purchased a new position in Xeris Biopharma in the 4th quarter worth $34,000. R Squared Ltd acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at about $42,000. Cibc World Markets Corp purchased a new position in shares of Xeris Biopharma in the fourth quarter worth about $44,000. Raymond James Financial Inc. acquired a new stake in shares of Xeris Biopharma during the fourth quarter worth about $45,000. Finally, Two Sigma Advisers LP purchased a new stake in Xeris Biopharma in the fourth quarter valued at approximately $47,000. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on XERS. Piper Sandler reaffirmed a "neutral" rating and set a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective (up previously from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Leerink Partners raised their target price on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a research note on Friday, March 7th. Craig Hallum upped their price target on Xeris Biopharma from $5.00 to $6.50 and gave the stock a "buy" rating in a research report on Friday, March 7th. Finally, Jefferies Financial Group reissued a "buy" rating and issued a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $6.10.

Xeris Biopharma Stock Performance

XERS stock traded down $0.09 during trading on Monday, reaching $4.02. The company had a trading volume of 1,655,052 shares, compared to its average volume of 1,861,448. The company has a market cap of $618.84 million, a price-to-earnings ratio of -8.93 and a beta of 1.37. Xeris Biopharma has a twelve month low of $1.69 and a twelve month high of $6.07. The firm has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $3.71.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.